The National Institutes of Health will conduct two clinical trials of the smallpox drug TPOXX (tecovirimat) -- one in the Democratic Republic of the Congo and another in the United States -- to see whether the drug can be safely and effectively used to treat monkeypox, including in the outpatient setting, the White House said in a fact sheet published Thursday (Aug. 11). The announcement follows the White House’s publication last month of its broader $140 million monkeypox research plan...